A Phase 2 interventional study of HEAD DOWN TILT -10° to -15° in Acute Ischemic Stroke, sponsored by University of Milano Bicocca. Recruiting at 6 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by University of Milano Bicocca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Ischemic Stroke with a site in Italy — 23 open to participants now, 29 under way, 2 of them phase 3. Ischemic Stroke · Italy.
Among the 81 studies in Ischemic Stroke with a site in Italy, this one is the 31st largest by planned enrollment of the 50 interventional ones that give a count, is one of 11 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 8 of the 28 other live ones, and was the 65th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →23 of the 81 studies in Ischemic Stroke with a site in Italy are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Italy, Belgium, Germany and 3 more countries
Ages 18+
Niguarda Hospital · Sites in Italy
Ages 18+
Azienda Usl di Bologna · Sites in Italy
Ages 18+
Italian Society of Vascular and Endovascular Surgery · Sites in Italy
Ages 45–90
Corxel Pharmaceuticals · Sites in Italy, United States, Belgium and 18 more countries
Ages 18–90
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 10 · Phase 4 5
First in 2000; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 118 is close to the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 227 across the 50 interventional studies, 550 across the 30 observational. Of the 40 that completed or were terminated, 13 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 81 have an industry lead sponsor. The 10 most frequent:
University of Milano Bicocca is the lead sponsor of 126 studies on the registry; 47 are open to participants now.
University of Milano Bicocca has 2 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
7 of the studies in Ischemic Stroke with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06710028Fondazione Policlinico Universitario Agostino Gemelli IRCCSTrustworthy Artificial Intelligence for Improvement of Stroke Outcomes | 2026-11-30 |
| NCT07199322Fondazione Don Carlo Gnocchi ETSClinical validatiOn of an AI-based DEcision Support System for Robotic Upper Limb Rehabilitation in Patients With Stroke. A CO-AIDER Study. | 2026-12 |
| NCT04562194VesalioNeVa ONE Registry Study | 2026-12-31 |
| NCT04339699Nobles Medical Technologies II IncNobleStitch EL STITCH Trial is a PFO Comparative Trial | 2026-12-31 |
| NCT06823466University of L'AquilaAdvancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants | 2027-02-12 |
Add all 7 to your calendar (.ics) → With an account.
Among the 81 studies in Ischemic Stroke with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The DOWN-SUITE study is multicenter, randomised, controlled, open-label clinical trial with blinded outcome assessment comparing collateral status in patients with acute ischemic stroke treated with an in-hospital application of head down tilt -10° to -15° (HDT15) versus usual positioning (0° to +30°) before endovascular mechanical thrombectomy.
This study will involve adult patients who are eligible for mechanical thrombectomy and who have acute ischemic stroke due to left or right middle cerebral artery occlusion (M1 segment).
The investigators hypothesise that HDT15, applied in acute ischemic stroke patients with a large vessel occlusion, will improve collateral circulation, prolong the survival of the ischemic penumbra and improve the clinical benefit from mechanical thrombectomy compared with standard of care (usual positioning 0° to +30°).
Investigating, developing and implementing a collateral therapeutic is a major objective in stroke research. The aim is to increase the amount of potentially salvageable penumbral tissue and expand the tissue time window, thus increasing the efficacy of reperfusion therapies and improving clinical outcomes.
Head down tilt 15° (HDT15) is a positional therapy consisting of tilting the patient with the head 15 degrees below the rest of the body. Experimental studies from an Italian-French group (Dr. Simone Beretta, Fondazione IRCCS San Gerardo dei Tintori and Prof. Tae-Hee Cho, Hospices Civils de Lyon) showed that HDT15 increased cerebral blood flow and improved functional outcome and infarct volume in randomised rats with middle cerebral artery (MCA) occlusion followed by reperfusion. Subsequent perfusion MRI experiments using the same stroke model by our group confirmed that HDT15 application for 60 minutes significantly increases collateral flow in the ischemic area.
There is no consensus in current clinical practice regarding the most appropriate head position for acute ischemic stroke (AIS) patients. The sitting position at +30° is the most common. An international cluster-randomised trial, HeadPoST, randomised over 11000 patients with acute stroke (85% ischemic) to either a lying-flat position or a sitting-up position (head elevated to at least 30°), maintained for 24 hours. No difference in the primary efficacy outcome (disability at 90 days measured with the modified Rankin Scale (mRS)), mortality, or rates of other serious adverse events, including pneumonia, were observed. However, the HeadPoST trial primarily targeted patients with mild symptoms without a large vessel occlusion (LVO), who were randomised beyond the usual time window of reperfusion therapies.
One retrospective study (pre-thrombectomy era) compared two cohorts of AIS patients with a LVO: patients with a standard position (0 to 30°; N=119), versus those with a HDT15 position (0 to -15°; N=90). The results suggested that HDT15 promotes neurological improvement compared to the standard position. No difference in serious adverse events was observed between the two cohorts.
A recent randomized, pilot clinical trial showed promising results of -20° head down positioning on long-term disability and an excellent safety profile.
Thus, the available clinical evidence raised no safety concern for HDT15 in AIS patients, but data on its efficacy, notably among AIS patients treated by MT, remains insufficient. HDT15, for its simplicity, low cost and feasibility, might be an optimal collateral therapeutic candidate to prolong the survival of the ischemic penumbra and improve the clinical benefit from reperfusion therapies with disability reduction. HDT15 is readily feasible by Emergency Services in the prehospital phase of AIS, before reperfusion therapies.
The DOWN-SUITE study will be the first multicenter, randomised, controlled, open-label clinical trial with blinded outcome assessment comparing collateral status in patients with AIS treated with an in-hospital application of HDT15 versus usual positioning before MT. The duration of HDT15 application (approximately 60-90 minutes) is expected to be long enough to detect significant changes in cerebral hemodynamics. Building from preclinical experiments on rodent and non-human primate stroke models carried out by our French-Italian group, it will provide for the first time the translation of HDT15 efficacy on cerebral hemodynamics and clinical outcome from animal models to AIS patients.
No therapeutic intervention is currently available to enhance collaterals in AIS.
The DOWN-SUITE trial will provide robust, high-quality evidence on the safety, feasibility and efficacy of HDT15 as a low-cost collateral therapeutic for AIS.
The investigators hypothesise that HDT15 (-10° to -15°), applied in AIS patients with an LVO, will improve collateral circulation, prolong the survival of the ischemic penumbra and improve the clinical benefit from MT compared with standard of care (usual positioning: 0° to +30°).
The investigators aim to perform a prospective, multicenter, proof of concept, randomised, controlled, open-label study. As a double-blind is not possible, a blinded central imaging core lab, whose members will be unaware of the procedure assignments, will assess all imaging outcomes, including the primary efficacy outcome.
This study will involve adult patients who are eligible for MT and who have AIS due to left or right MCA occlusion (M1 segment).
Benefit/risk ratio The investigators hypothesise that HDT15 would improve cerebral collaterals in patients randomised in the intervention group, which could subsequently reduce the ischemic injury and improve the clinical outcome.
No harm from participating in DOWN-SUITE is expected for patients in the intervention or control groups. Previous clinical data on HDT15 raised no safety concerns. No difference in post-stroke complications, including cerebral oedema or haemorrhage, pneumonia or mortality, was observed in a retrospective observational study. HDT15 is not expected to interfere with standard care, including the procedural steps of MT. Mild discomfort related to the tilted position may occur in some patients. The treating physician will continuously monitor all patients during the entire duration of the HDT15 application. No additional risk is expected in patients in the control group, as they will receive standard care.
Overall, this study's benefit/risk ratio is considered very favourable.
This study could potentially establish HDT15 as the first evidence-based collateral therapeutic for AIS. No therapeutic intervention is currently available to enhance collaterals in the acute phase of ischemic stroke. Such a collateral-enhancing therapy is necessary to expand the time window and increase the probability of successful reperfusion with IVT and MT, resulting in better clinical outcomes.
The results of the DOWN-SUITE trial may pave the way for larger randomised controlled trials of HDT15 in a wider stroke patient population, such as patients transferred from spoke hospitals to hub stroke centers to receive thrombectomy and unselected patients with suspected AIS in the prehospital setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Major breath disorders, defined as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HDT15 will be applied in the intervention group in 2 different settings: * in the Emergency Room, by tilting the stretcher to lower the head by -10° to -15° relative to the body of the patient; the degree of tilting will be checked using a dedicated digital inclinometer or a mobile phone app * in the Angiography Suite, by tilting the angiography table to lower the head by -10° to -15° relative to the body of the patient, depending on the actual technology of the angiography system of each clinical site; the degree of tilting will be automatically checked using the angiography system HDT15 will start as soon as possible following randomisation in the Emergency Room (i.e. after vascular neuroimaging), and will be maintained during the transfer to the Angiography Suite, as well as during the entire thrombectomy procedure. HDT15 will end after the completion of mechanical thrombectomy.
Procedure: HEAD DOWN TILT -10° to -15°
Patients randomised in the control group will be maintained in the usual position during the emergency room phase (0° to +30°) and on the angiography table (0°), according to standard practice. Mechanical thrombectomy will be performed as per usual care.
Head down tilt -10° to -15° (HDT15) is a positional therapy consisting of tilting the patient with the head -10° to -15° degrees below the rest of the body. Application of HDT15 will not delay usual care. The standard in-hospital patient pathway, including transfer from neuroimaging room to the angiography suite and the required procedural steps of MT, will allow sufficient time for the application of HDT15. HDT15 duration is expected to be at least 30 minutes (estimated time 30 to 90 minutes), from start to the assessment of the primary efficacy endpoint. The actual degree of HDT15 will be a range between -10° to -15°, depending on the angiographic system of each clinical site, but it will be maintained at -15° during the Emergency Room phase which is expected to account for \>50% of the total application time.
Good collateral status
The primary endpoint will be the achievement of good collateral status, i.e. grade 3 or 4 on the American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) collateral scale, in the HDT15 versus control group, as seen at the beginning of MT.15 The ASITN/SIR collateral grade will be assessed by a blinded central imaging core lab from the pretreatment diagnostic angiographic runs, routinely performed as the first procedural step of MT.
Time frame: Day 0 (during mechanical thrombectomy)
Feasibility of HDT15
proportion of patients randomised to the intervention group who are able to maintain HDT15 during the entire MT procedure
Time frame: Day 0 (in the emergency room and angio suite)
Delay to thrombectomy
hospital admission-to-arterial access time (i.e. time to arterial puncture)
Time frame: Day 0 (in the emergency room and angio suite)
Vomiting
Proportion of patients presenting one or more episodes of vomiting from randomisation to the completion of MT
Time frame: Day 0 (in the emergency room and angio suite)
Early neurological deterioration
Proportion of patients who had increase of ≥4 points on the NIHSS score within 24±12 hours of the randomisation
Time frame: 1 day (24±12 hours)
Symptomatic intracranial hemorrhage
Proportion of patients who had SICH per SITS-MOST definition within 24±12 hours: type 2 parenchymal hematoma with neurological deterioration of ≥4 points on the NIHSS
Time frame: 1 day (24±12 hours)
Aspiration pneumonia
Proportion of patients with pneumonia within the first 72 hours after randomisation
Time frame: 1 day (24±12 hours)
Neurological disability
functional outcome at 3 months, assessed with the ordinal score on the modified Rankin scale (shift across outcomes on the mRS between groups)
Time frame: 3 months
Systolic blood pressure
Mean values of systolic blood pressure (mmHg) from hospital admission to the end of MT; monitored at entry in the Emergency Room, at entry in the angio suite and every 15 minutes from the start to the end of MT
Time frame: Day 0 (in the emergency room and angio suite)
Diastolic blood pressure
Mean values of diastolic blood pressure (mmHg) from hospital admission to the end of MT; monitored at entry in the Emergency Room, at entry in the angio suite and every 15 minutes from the start to the end of MT
Time frame: Day 0 (in the emergency room and angio suite)
Oxygen saturation
Mean values of oxygen saturation (%) from hospital admission to the end of MT; these physiological parameters will be monitored at entry in the Emergency Room, at entry in the angio suite and every 15 minutes from the start to the end of MT
Time frame: Day 0 (in the emergency room and angio suite)
Plan to share: Yes — The project data can be accessed by interested European and extra-EU third parties for replication or further analysis only if given in a completely anonymous form. Third parties in this project include academic institutions, research centers and non-profit associations (e.g. research consortia). Third parties in this project do not include profit associations (e.g. drug companies).
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: After completion of the primary analysis
Access criteria: If the need arises to communicate data in pseudo-anonymous form, the patient will, first of all, be informed and specific informed consent will be provided. In the latter case, the data will not be sent without the patient's consent. Ad hoc Data Transfer Agreements will be established with the interested third parties.
Started Mar 2025 (actual). Primary completion is estimated for Sep 2026, 18 months after the start.
Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 18 months is below that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Milano Bicocca →